This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Sol Katz, MD

JAMA. 1970;212(12):2113-2114.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The introduction of isoniazid for the treatment of tuberculosis was accompanied by justified warnings, based on previous experience with streptomycin, that its improper use would result in the rapid development of tubercle bacilli resistant to this potent agent. Improper use was tantamount to the administration of isoniazid as a single agent rather than as a part of a combined drug regimen.

The concept of prolonged combination therapy with isoniazid as one of the agents has firm support experimentally and in controlled clinical trials. Furthermore, studies of bacterial genetics have established the patterns by which resistant bacilli develop. It is through the use of such combined therapy that the appearance of resistant mutants is discouraged. Thus, assuming proper case finding, intelligently applied chemotherapy should control the vast majority of cases of tuberculosis.

Since many factors must be involved in the ultimate eradication of tuberculosis, not the least of which is social, . . . [Full Text PDF of this Article]

Author Affiliations
Georgetown University School of Medicine Washington, DC

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?